Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.

Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM.

PLoS One. 2009;4(4):e5401. doi: 10.1371/journal.pone.0005401. Epub 2009 Apr 30.

2.

A genetic mouse model for metastatic lung cancer with gender differences in survival.

Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G.

Oncogene. 2007 Oct 18;26(48):6896-904. Epub 2007 May 7.

PMID:
17486075
3.

Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.

Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, Carrara M, Fiore A, Nuzzo S, Bicciato S, Nanni P, Landuzzi L, Cavallo F, Calogero R, Quaglino E.

BMC Genomics. 2014;15 Suppl 3:S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6.

4.

Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.

Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, Hezel AF, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK.

Carcinogenesis. 2008 Apr;29(4):747-53. doi: 10.1093/carcin/bgn050. Epub 2008 Feb 17.

PMID:
18283039
5.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

6.

Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.

Sarkar FH, Li Y, Vallyathan V.

Int J Mol Med. 2001 Oct;8(4):453-9.

PMID:
11562787
7.

Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.

Huang CL, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M, Hadama T, Miyake M.

Int J Oncol. 1998 Mar;12(3):553-63.

PMID:
9472092
8.

A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.

Wang Y, Zhang Z, Lubet RA, You M.

Oncogene. 2006 Feb 23;25(8):1277-80.

PMID:
16247444
9.

miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Kasinski AL, Slack FJ.

Cancer Res. 2012 Nov 1;72(21):5576-87. doi: 10.1158/0008-5472.CAN-12-2001. Epub 2012 Sep 10.

10.

Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.

Ali A, Bhatti MZ, Shah AS, Duong HQ, Alkreathy HM, Mohammad SF, Khan RA, Ahmad A.

J Biol Chem. 2015 Aug 28;290(35):21336-51. doi: 10.1074/jbc.M114.635730. Epub 2015 Apr 24.

11.

K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.

Li S, Rosell R, Urban A, Font A, Ariza A, Armengol P, Abad A, Navas JJ, Monzo M.

Lung Cancer. 1994 Jul;11(1-2):19-27.

PMID:
8081702
12.

Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.

Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie J, Cadranel J, Wislez M.

Int J Cancer. 2014 Feb 15;134(4):765-77. doi: 10.1002/ijc.28413. Epub 2013 Sep 4.

13.

Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.

Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW.

PLoS One. 2008 May 7;3(5):e2125. doi: 10.1371/journal.pone.0002125.

14.

Allele-specific detection of K-ras oncogene expression in human non-small-cell lung carcinomas.

Slebos RJ, Habets GG, Evers SG, Mooi WJ, Rodenhuis S.

Int J Cancer. 1991 Apr 22;48(1):51-6.

PMID:
1850383
15.

Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.

Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM.

PLoS One. 2008 May 21;3(5):e2220. doi: 10.1371/journal.pone.0002220.

16.

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique..

Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20.

17.

Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.

Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC.

Neoplasia. 2009 Aug;11(8):763-70.

19.

Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.

Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, Choi YL, Park WY, Lee HM, Seol HJ, Shim YM, Joo KM, Nam DH.

Clin Cancer Res. 2015 Mar 1;21(5):1172-82. doi: 10.1158/1078-0432.CCR-14-1589. Epub 2014 Dec 30.

20.

Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.

Schuster K, Venkateswaran N, Rabellino A, Girard L, Peña-Llopis S, Scaglioni PP.

Mol Cancer Res. 2014 Jun;12(6):912-23. doi: 10.1158/1541-7786.MCR-13-0620-T. Epub 2014 Mar 11.

Supplemental Content

Support Center